S. Korea's Stem Cell Research Bounces Back From Decade-Old Scandal
This article was originally published in PharmAsia News
South Korea's regenerative-medicine research appears to have bounced back from a national scandal involving faked papers in 2005 to the point one of its research centers has more than 1,000 scientists working on the subject.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.